MyStocks

MEMBER'S LOGINX

Remember Username
Keep me signed in

(Please do not use this option on a public machine)

Home
Research It
TORRENT PHARMACEUTICALS LIMITED (pharmaceuticals)
TORRENT PHARMACEUTICALS LIMITED Financial Data

Torrent Pharma Fact Sheet (TORR)

Mail
Print
FaceBook
Twitter
Linked In
WhatsApp

Here is the latest financial fact sheet of Torrent Pharma. For more details, see the Torrent Pharma quarterly results and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

TORRENT PHARMA Price History

Price	Rs	1,660.7
Mkt Cap	Rs m	281,082
Vol	'000	4.4
P/E	X	44.8
P/CF	X	25.9
EPS (TTM)	Rs	37.1

% ch	%	-0.7
No. of shares	m	169.26
% ch week	%	0.9
% ch 1-mth	%	2.3
% ch 12-mth	%	30.8
52 week H/L	Rs	1,872.0/1,223.8

(As on Nov 16, 2018 (Close))

» Best Performing pharmaceuticals Stocks

1d 1w 1m 3m 6m 1y 3y 5y Max

* Results Consolidated

EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

TORRENT PHARMA Financials

No. of Mths Year Ending	12 Mar-14*	12 Mar-15*	12 Mar-16*	12 Mar-17*	12 Mar-18*	5-Yr Chart Click to enlarge

TORRENT PHARMA EQUITY SHARE DATA
High	Rs	578	1,232	1,720	1,768	1,550
Low	Rs	334	523	1,134	1,186	1,144
Sales per share (Unadj.)	Rs	247.3	275.0	394.5	346.1	354.7
Earnings per share (Unadj.)	Rs	39.2	44.4	102.4	55.2	40.1
Diluted earnings per share	Rs	39.2	44.4	102.4	55.2	40.1
Cash flow per share (Unadj.)	Rs	44.4	55.6	116.5	73.3	64.2
Dividends per share (Unadj.)	Rs	10.00	11.25	40.00	14.00	14.00
Adj. dividends per share	Rs	10.00	11.25	39.99	14.00	14.00
Dividend yield (eoy)	%	2.2	1.3	2.8	0.9	1.0
Book value per share (Unadj.)	Rs	112.4	156.2	206.5	257.1	273.1
Adj. book value per share	Rs	112.4	156.1	206.4	257.0	273.1
Shares outstanding (eoy)	m	169.22	169.22	169.22	169.22	169.22
Bonus/Rights/Conversions		B1:1	-	-	-	-
Price / Sales ratio	x	1.8	3.2	3.6	4.3	3.8
Avg P/E ratio	x	11.6	19.8	13.9	26.8	33.6
P/CF ratio (eoy)	x	10.3	15.8	12.3	20.1	21.0
Price / Book Value ratio	x	4.1	5.6	6.9	5.7	4.9
Dividend payout	%	25.5	25.4	39.1	25.4	34.9
Avg Mkt Cap	Rs m	77,190	148,465	241,435	249,887	227,897
No. of employees	`000	9.5	11.0	10.9	11.8	14.7
Total wages/salary	Rs m	7,411	8,418	8,424	9,934	11,353
Avg. sales/employee	Rs Th	4,386.5	4,212.4	6,129.6	4,971.5	4,083.0
Avg. wages/employee	Rs Th	776.8	762.0	773.4	843.2	772.3
Avg. net profit/employee	Rs Th	695.9	679.8	1,591.3	792.4	461.3

TORRENT PHARMA INCOME DATA
Net Sales	Rs m	41,847	46,535	66,764	58,569	60,021
Other income	Rs m	381	2,856	2,256	2,233	2,988
Total revenues	Rs m	42,229	49,390	69,020	60,802	63,009
Gross profit	Rs m	9,515	10,202	27,330	13,773	13,493
Depreciation	Rs m	870	1,907	2,376	3,069	4,086
Interest	Rs m	586	1,752	1,840	2,056	3,085
Profit before tax	Rs m	8,440	9,398	25,371	10,881	9,310
Minority Interest	Rs m	0	0	0	0	0
Prior Period Items	Rs m	0	0	0	0	0
Extraordinary Inc (Exp)	Rs m	0	0	-1,936	0	0
Tax	Rs m	1,801	1,888	6,102	1,545	2,529
Profit after tax	Rs m	6,639	7,509	17,333	9,336	6,781
Gross profit margin	%	22.7	21.9	40.9	23.5	22.5
Effective tax rate	%	21.3	20.1	24.1	14.2	27.2
Net profit margin	%	15.9	16.1	26.0	15.9	11.3

TORRENT PHARMA BALANCE SHEET DATA
Current assets	Rs m	34,045	40,983	46,882	48,794	52,623
Current liabilities	Rs m	21,746	27,046	32,855	27,383	52,022
Net working cap to sales	%	29.4	30.0	21.0	36.6	1.0
Current ratio	x	1.6	1.5	1.4	1.8	1.0
Inventory Days	Days	88	84	74	97	120
Debtors Days	Days	96	125	79	59	76
Net fixed assets	Rs m	14,095	34,720	39,007	42,079	85,016
Share capital	Rs m	846	846	846	846	846
"Free" reserves	Rs m	17,272	25,583	34,095	42,655	45,376
Net worth	Rs m	19,024	26,430	34,941	43,501	46,222
Long term debt	Rs m	7,445	21,729	18,501	22,408	41,115
Total assets	Rs m	50,698	79,641	90,579	97,021	142,432
Interest coverage	x	15.4	6.4	14.8	6.3	4.0
Debt to equity ratio	x	0.4	0.8	0.5	0.5	0.9
Sales to assets ratio	x	0.8	0.6	0.7	0.6	0.4
Return on assets	%	14.3	11.6	21.2	11.7	6.9
Return on equity	%	34.9	28.4	49.6	21.5	14.7
Return on capital	%	34.1	23.2	47.3	19.6	14.2
Exports to sales	%	37.4	30.4	43.3	0	0
Imports to sales	%	8.2	6.0	6.9	0	0
Exports (fob)	Rs m	15,665	14,136	28,934	0	0
Imports (cif)	Rs m	3,416	2,801	4,584	0	0
Fx inflow	Rs m	16,862	14,265	29,185	20,066	14,580
Fx outflow	Rs m	5,196	5,184	6,021	5,304	3,600
Net fx	Rs m	11,666	9,081	23,165	14,762	10,980

TORRENT PHARMA CASH FLOW
From Operations	Rs m	5,994	8,102	27,421	10,088	8,942
From Investments	Rs m	-3,558	-21,623	-8,379	-7,869	-47,070
From Financial Activity	Rs m	864	12,123	-14,352	-1,929	34,174
Net Cashflow	Rs m	3,300	-1,399	4,375	177	-3,655

* Results Consolidated

Source: Company Annual Reports, Regulatory Filings, Equitymaster

» Historical quarterly results for torrent pharmaceuticals limited

Share Holding

Indian Promoters	71.5%
Foreign collaborators	0.0%
Indian inst/Mut Fund	7.0%
FIIs	12.6%
ADR/GDR	0.0%
Free float	8.8%
Shareholders	26,511
Pledged promoter(s) holding	0.0%

Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Views on news

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
Add To MyStocks

TORRENT PHARMA - ADCOCK INGRAM COMPARISON

Compare Company With Charts

COMPARE TORRENT PHARMA WITH

MARKET STATS

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS

PREMIUM PRODUCTS

QUICK LINKS

APPS

FOLLOW

Follow @Equitymaster

Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Testimonials